# EDGAR Filing Document

**Accession Number:** 0001121404
**File Stem:** 0001121404-23-000002
**Filing Date:** 2023-2
**Character Count:** 108606
**Document Hash:** 6bf9f159c3c3ef1664ee6d2cf88f2350
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001121404-23-000002.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001121404-23-000002

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sanofi
- **CENTRAL INDEX KEY:** 0001121404
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 133529324
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31368
- **FILM NUMBER:** 23584471

**BUSINESS ADDRESS:**
- **STREET 1:** 46 AVENUE DE LA GRANDE ARMEE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75017
- **BUSINESS PHONE:** 33153774400

**MAIL ADDRESS:**
- **STREET 1:** 46 AVENUE DE LA GRANDE ARMEE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SANOFI-AVENTIS
- **DATE OF NAME CHANGE:** 20040826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SANOFI SYNTHELABO SA
- **DATE OF NAME CHANGE:** 20010104

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2023**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**46, avenue de la Grande Armée, 75017 Paris, FRANCE**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No ☒

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

------

In February 2023, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

**Exhibit Index**

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description</u> |
| Exhibit 99.1 | Press release dated February 3, 2023: Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone  |

---

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 3, 2023 |  | SANOFI |
|  | By: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ Alexandra Roger |
|  | Name: | Alexandra Roger |
|  | Title: | Head of Securities Law and Capital Markets |

---

## Exhibit 99.1

**Press Release** ![image.jpg](image.jpg)

*Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone* 

**Paris, February 3, 2023**

**Q4 2022 sales growth of 2.6% at CER and business EPS**<sup>(1)</sup> **growth of 17.4% at CER**

• Specialty Care grew 18.1% driven by Dupixent<sup>®</sup> (€2,402 million, +42.1%) and new product launches

• Vaccines sales (-16.3%) reflecting influenza and PPH sales phasing (Q3 influenza sales: up 32.4%) as well as ramp up of non-consolidated Vaxelis<sup>®</sup> sales

• General Medicines core assets up 8.0% while GBU sales were lower (-3.7%) mainly due to Lantus<sup>®</sup> and spin-off of EUROAPI

• CHC sales increased 6.6% driven by double-digit growth of Digestive Wellness, Cough & Cold and Allergy categories

**Full-year 2022 delivered 7.0% sales growth and 17.1% business EPS growth at CER**

• Sales grew to €42,997 million driven by Dupixent<sup>®</sup> (€8,293 million, +43.8%), adding €3 billion of incremental sales, Vaccines up 6.3% in line with the mid-term growth objective as well as CHC strategy execution (+8.6%)

• Mid-term BOI margin target of 30% and cost savings objective of €2.5 billion achieved

• Business EPS<sup>(1)</sup> of €8.26 up 25.9% on a reported basis and 17.1% at CER

• IFRS EPS of €5.37 (up 8.0%)

• Board held on February 2, proposes annual dividend of €3.56, an increase of 6.9%

**Progress on Corporate Social Responsibility strategy in Q4**

• Positive phase 2/3 results of acoziborole with the potential to further transform the treatment of sleeping sickness

• Accelerating our ambition towards net zero emissions by 5 years, now targeting 2045

**Key R&D milestones and regulatory achievements in Q4**

• Dupixent<sup>®</sup> approved in Europe for prurigo nodularis and CHMP positive opinion for eosinophilic esophagitis

• Beyfortus<sup>®</sup> *(*nirsevimab) approved in Europe for the prevention of RSV disease in all infants

• VidPrevtyn<sup>®</sup> Beta approved in Europe as a booster for the prevention of COVID-19 in adults

• Enjaymo<sup>®</sup> approved in Europe in adult patients with cold agglutinin disease (CAD)

**Full-year 2023 business EPS guidance** 

• Sanofi expects 2023 business EPS<sup>(1)</sup> to grow low single digit<sup>(2)</sup> at CER, barring unforeseen major adverse events. Applying average January 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -3.5% to -4.5%

***Sanofi Chief Executive Officer, Paul Hudson, commented:***

*"We closed 2022, marking the successful execution of the first chapter of our 6-year 'Play to Win' strategy. Specialty Care delivered the highest sales among our businesses. Dupixent*<sup>®</sup> *and Vaccines continue to be our leading growth drivers. We are particularly proud of the progress we made in R&D transformation with multiple approvals of transformative medicines and new product launches across Specialty Care. At the same time, we keep delivering strong proof points of our improved financial performance underpinned by the achievement of the 30% BOI margin. Moving to the next chapter of our strategy, we are looking forward to the planned launches of Altuviiio*<sup>®</sup> *and Beyfortus*<sup>®</sup> *as well as key pivotal readouts, including the COPD indication for Dupixent*<sup>®</sup>*. With the view on the expected entrants of generic competition for Aubagio*<sup>®</sup> *in the coming months, we remain confident in our outstanding commercial capabilities, including the ambition to reach sales of 10 billion euros for Dupixent*<sup>®</sup> *in 2023, enabling us to guide to low single-digit EPS growth for the year."*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Q4 2022** | ***Change*** | ***Change <br>at CER*** | **2022** | ***Change*** | ***Change <br>at CER*** |
| IFRS net sales reported | €10,725m | *+7.3%* | *+2.6%* | €42,997m | *+13.9%* | *+7.0%* |
| IFRS net income reported | €1,460m | *+29.1%* | *_* | €6,720m | *+8.0%* | *—* |
| IFRS EPS reported | €1.16 | *+28.9%* | *_* | €5.37 | *+8.0%* | *—* |
| Free cash flow<sup>(3)</sup> | €2,546m | *+0.2%* | *_* | €8,483m | *+4.8%* | *—* |
| Business operating income | €2,724m | *+20.7%* | *+15.0%* | €13,040m | *+21.7%* | *+13.3%* |
| Business net income<sup>(1)</sup> | €2,141m | *+23.8%* | *+17.6%* | €10,341m | *+25.9%* | *+17.0%* |
| Business EPS<sup>(1)</sup> | €1.71 | *+23.9%* | *+17.4%* | €8.26 | *+25.9%* | *+17.1%* |

---

*Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q4 2022 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).*

------

*2022 fourth-quarter and full-year Sanofi sales*

----------------------------

*Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER*<sup>1</sup>

---------------------

In the fourth quarter of 2022, Sanofi sales were €10,725 million, up 7.3% on a reported basis. Exchange rate movements had a positive effect of 4.7 percentage points, mainly due to the U.S. dollar. At CER, company sales were up 2.6%.

In 2022, Sanofi sales reached €42,997 million, up 13.9% on a reported basis. Exchange rate movements had a positive effect of 6.9 percentage points. At CER, company sales were up 7.0%.

**Global Business Units**

**Fourth-quarter 2022 net sales by Global Business Unit (variation at CER; € million; % of total sales)**

![chart-8f98b6910d09426f888.jpg](chart-8f98b6910d09426f888.jpg)

**Fourth-quarter 2022 net sales by geographic region (variation at CER; € million; % of total sales)**

![chart-77caa408d3724fb9a48.jpg](chart-77caa408d3724fb9a48.jpg)

**Fourth-quarter 2022 operating income**

Fourth-quarter **business operating income** (BOI) increased 20.7% to €2,724 million. At CER, BOI increased 15.0%. The ratio of BOI to net sales increased 2.8 percentage point to 25.4% (25.3% at CER). In 2022, BOI increased 21.7% to €13,040 million. At CER, BOI increased 13.3%. The ratio of business operating income to net sales increased 1.9 percentage point to 30.3% (30.0% at CER).

<sup>1</sup> *See Appendix 9 for definitions of financial indicators.*

------

*Pharmaceuticals*

Fourth-quarter Pharmaceutical sales increased 7.3% to €7,793 million, mainly driven by the Specialty Care portfolio (up 18.1%) with continued strong performance of Dupixent<sup>®</sup> while sales in General Medicines decreased 3.7%. In 2022, Pharmaceuticals sales increased 6.9% to €30,688 million reflecting the strong performance of Specialty Care and General Medicines core assets.

**Specialty Care**

**Dupixent**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| **Total Dupixent**<sup>®</sup> | **2402** | ***+42.1*** *%*** | **8293** | ***+43.8*** *%*** |

---

In the fourth quarter, **Dupixent**<sup>®</sup> (collaboration with Regeneron) sales increased 42.1% to €2,402 million. In the U.S., Dupixent<sup>®</sup> sales of €1,890 million (up 43.8%) were driven by continued strong demand in the approved indications, atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and the strong launches of AD in children as young as 6 months as well as eosinophilic esophagitis and prurigo nodularis. Dupixent<sup>®</sup> total prescriptions (TRx) increased 34% (y*ear-over-year*) and new-to-brand prescriptions (NBRx) grew 48%. In Europe, fourth-quarter Dupixent<sup>®</sup> sales grew 33.2% to €249 million reflecting continued growth in AD, asthma and CRSwNP. In the Rest of the World region, fourth-quarter sales reached €263 million, up 40.1%, driven mainly by sales in Japan and China. Full-year 2022 Dupixent<sup>®</sup> sales reached €8,293 million, up 43.8%.

**Neurology and Immunology**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br> at CER*** | **2022** | ***Change <br> at CER*** |
| Aubagio<sup>®</sup> | 493 | *-4.6 %* | 2031 | *-4.3 %* |
| Lemtrada<sup>®</sup> | 17 | *-15.8 %* | 80 | *-8.5 %* |
| Kevzara<sup>®</sup> | 79 | *-17.6 %* | 339 | *+11.8 %* |
| **Total Neurology and Immunology** | **589** | ***-7.0*** *%*** | **2450** | ***-2.5*** *%*** |

---

Fourth-quarter and full-year 2022 **Neurology and Immunology** sales decreased 7.0% (to €589 million) and 2.5%, respectively, mainly due to lower Aubagio<sup>®</sup> sales.

**Aubagio**<sup>®</sup> sales decreased 4.6% in the fourth quarter to €493 million mainly due to lower sales in the Rest of the World region as a result of generic competition in Canada. In the U.S., generics of teriflunomide could enter the market on March 12, 2023, as settled with generic makers in 2017. In Europe, teriflunomide generic competition is expected in the fourth quarter of 2023.

Fourth-quarter **Kevzara**<sup>®</sup> (collaboration with Regeneron) sales decreased 17.6% to €79 million due to lower sales in Europe and the Rest of the World region. This is due to a high base in the fourth quarter of 2021 which benefitted from a temporary increased global demand for IL-6 receptor blockers.

**Rare Disease**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Myozyme<sup>®</sup> / Lumizyme<sup>®</sup> | 216 | *-17.7 %* | 958 | *-8.8 %* |
| Fabrazyme<sup>®</sup> | 240 | *+3.6 %* | 938 | *+5.2 %* |
| Cerezyme<sup>®</sup> | 159 | *-8.3 %* | 707 | *+2.6 %* |
| Cerdelga<sup>®</sup> | 71 | *+1.5 %* | 288 | *+6.7 %* |
| Aldurazyme<sup>®</sup> | 65 | *+1.6 %* | 267 | *+6.6 %* |
| Nexviazyme<sup>®</sup>/Nexviadyme<sup>®</sup> | 65 | *+306.7 %* | 196 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*–* |
| Others Rare Disease | 34 | *+126.7 %* | 91 | *+11.0 %* |
| **Total Rare Disease** | **850** | ***+1.8*** *%*** | **3445** | ***+5.7*** *%*** |

---

In the fourth quarter, **Rare Disease** sales increased 1.8% to €850 million driven by the launch of **Xenpozyme**<sup>TM</sup>. Full-year 2022 Rare Disease sales increased 5.7% reflecting growth across all three geographic regions and across all franchises.

Fourth-quarter sales of the **Pompe franchise** increased 0.4% to €281 million driven by the ramp up of Nexviazyme<sup>®/</sup>Nexviadyme<sup>®</sup> in the U.S., Europe and Japan. Sales of **Nexviazyme**<sup>®</sup>**/Nexviadyme**<sup>®</sup> were

------

€65 million in the fourth quarter (of which €49 million in the U.S.). **Myozyme**<sup>®</sup>**/Lumizyme**<sup>®</sup> sales decreased 17.7% to €216 million as a result of the conversion to Nexviazyme<sup>®</sup> in the eligible Pompe population (late-onset disease).

Sales of the **Gaucher** franchise decreased 5.6% (to €230 million) in the fourth quarter. **Cerezyme**<sup>®</sup> sales were down 8.3% to €159 million, mainly reflecting lower sales in the Rest of the World region due to unfavorable shipping patterns. **Cerdelga**<sup>®</sup> sales were up 1.5% driven by new patients and Cerezyme<sup>®</sup> switch.

Fourth-quarter **Fabrazyme**<sup>®</sup> sales increased 3.6% to €240 million, reflecting growth in the U.S. and the Rest of the World region.

**Xenpozyme**<sup>TM</sup> (olipudase alfa) was launched in the U.S., some European countries and Japan in 2022 as the first and only enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase. Fourth-quarter and full-year 2022 sales were €17 million and €21 million, respectively.

**Oncology** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Jevtana<sup>®</sup> | 87 | *-24.5 %* | 391 | *-20.0 %* |
| Sarclisa<sup>®</sup> | 86 | *+55.6 %* | 294 | *+60.2 %* |
| Fasturtec<sup>®</sup> | 47 | *+7.3 %* | 177 | *+8.6 %* |
| Libtayo<sup>®</sup> |  | *-100.0 %* | 88 | *-34.1 %* |
| **Total Oncology** | **221** | ***-11.7*** *%*** | **952** | ***-1.5*** *%*** |

---

Fourth-quarter **Oncology** sales decreased 11.7% (to €221 million) reflecting the end of consolidation of Libatyo<sup>®</sup> sales from the beginning of July. Excluding Libtayo<sup>®</sup>, Oncology sales were up 3.4% with Sarclisa<sup>®</sup> being the main driver. Full-year 2022 **Oncology** sales decreased 1.5% and increased 3.8% when excluding Libtayo<sup>®</sup> sales in both years.

Sanofi stopped consolidating Libtayo<sup>®</sup> non-U.S. sales from the third quarter of 2022 following the restructuring of its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Under the amended and restated license and collaboration agreement, Regeneron has obtained worldwide exclusive license rights to Libtayo<sup>®</sup>. Prior, the companies had split equally Libtayo<sup>®</sup>'s worldwide operating profits and co-commercialized Libtayo<sup>®</sup> in the U.S., with Sanofi solely responsible for commercialization in the rest of the world.

Fourth-quarter **Sarclisa**<sup>®</sup> sales were €86 million, up 55.6% primarily driven by performance in the U.S. Europe and Japan.

Fourth-quarter **Jevtana**<sup>®</sup> sales decreased 24.5% to €87 million due to the entry of generic competition in Europe at the end of March 2021 and lower sales in the U.S., reflecting increased competition. In the U.S., Jevtana<sup>®</sup> is currently covered by four Orange Book listed patents US 7,241,907, US 8,927,592, US 10,583,110 and US 10,716,777. Sanofi filed patent infringement suits under Hatch-Waxman against generic filers asserting the '110 patent, the '777 patent and the '592 patent in the US District Court for the District of Delaware. Sanofi has reached settlement agreements with most of the defendants and the suit against the only remaining defendant Sandoz is ongoing. In August 2022, the district court dismissed Sanofi's infringement claim related to the '592 patent. A 3-day trial took place on January 11-13 2023 and Sandoz has agreed not to launch any generic cabazitaxel product until the earlier of a district court decision in favor of Sandoz or four months after the completion of the post-trial briefing.

**Rare Blood Disorders** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Eloctate<sup>®</sup> | 138 | *-9.2 %* | 580 | *-5.9 %* |
| Alprolix<sup>®</sup> | 141 | *+14.2 %* | 504 | *+10.4 %* |
| Cablivi<sup>®</sup> | 62 | *+52.6 %* | 211 | *+20.7 %* |
| Enjaymo<sup>TM</sup> | 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*–* | 22 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*–* |
| **Total Rare Blood Disorders** | **352** | ***+11.3*** *%*** | **1317** | ***+5.6*** *%*** |

---

Fourth quarter and full-year 2022 **Rare Blood Disorders** franchise sales increased 11.3% (to €352 million) and 5.6% respectively, driven by Alprolix<sup>®</sup>, Cablivi<sup>®</sup> and the launch of Enjaymo™, more than offsetting lower Eloctate<sup>®</sup> sales.

------

**Eloctate**<sup>®</sup> sales were €138 million in the fourth quarter, down 9.2% reflecting lower sales in the U.S. due to competitive pressure.

Fourth-quarter **Alprolix**<sup>®</sup> sales were up 14.2% to €141 million driven by the Rest of the World region which includes sales to Sobi.

**Cablivi**<sup>®</sup> sales increased by 52.6% to €62 million in the fourth quarter supported by the performance in the U.S.

Fourth-quarter and full-year sales of **Enjaymo**™, the first approved treatment for patients with cold agglutinin disease were €11 million and €22 million, respectively (launched in the U.S. and Japan in 2022 and approved in Europe in November 2022).

**General Medicines** 

Fourth-quarter General Medicines sales decreased 3.7% to €3,379 million. The deconsolidation of EUROAPI<sup>2</sup> third party sales had a negative impact of -3.6 percentage point (ppt) and divestments of non-core assets -0.7 ppt. Fourth-quarter Industrial sales were €177 million, down 22.7% and reflected deconsolidation of EUROAPI third party sales from May 10.

Full-year 2022 General Medicines sales decreased 4.2% to €14,231 million. The deconsolidation of EUROAPI third party sales had a negative impact of -2.4ppt and divestments of non-core assets -0.8ppt in 2022. In 2022, Industrial sales were €620 million, down 26.2% and reflected deconsolidation of EUROAPI third party sales. In 2022, core assets<sup>3</sup> sales accounted for 47% of General Medicines sales compared with 43% in 2021 (excluding Industrial sales).

**Core assets**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Lovenox<sup>®\*</sup> | 289 | *-13.1 %* | 1310 | *-13.8 %* |
| Toujeo<sup>®</sup> | 272 | *+13.9 %* | 1117 | *+9.8 %* |
| Plavix<sup>®</sup> | 245 | *+11.7 %* | 983 | *+2.5 %* |
| Praluent<sup>®</sup> | 96 | *+70.9 %* | 376 | *+65.1 %* |
| Thymoglobulin<sup>®</sup> | 118 | *+26.4 %* | 446 | *+16.9 %* |
| Multaq<sup>®</sup> | 104 | *-6.1 %* | 383 | *+4.3 %* |
| Mozobil<sup>®</sup> | 69 | *+3.2 %* | 261 | *+4.3 %* |
| Soliqua<sup>®</sup> | 55 | *-5.6 %* | 215 | *+1.5 %* |
| Rezurock<sup>®</sup> | 63 | *+180.0 %* | 207 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*–* |
| Others | 287 | *+3.4 %* | 1091 | *-0.2 %* |
| **Total core assets** | **1598** | ***+8.0*** *%*** | **6389** | ***+5.2*** *%*** |

---

*\*Excluding Auto generics*

In the fourth quarter and full-year 2022, **core assets**<sup>3</sup> sales increased 8.0% (to €1,598 million) and 5.2%, respectively, mainly driven by growth of Praluent<sup>®</sup>, Toujeo<sup>®</sup>, Thymoglobulin<sup>®</sup> and as well as the strong performance of Rezurock<sup>®</sup>, partially offset by lower sales of Lovenox<sup>®</sup>.

Fourth-quarter **Lovenox**<sup>®</sup> sales decreased 13.1% to €289 million, reflecting lower COVID-19 related demand compared to 2021, leading to a decrease of the Low Weight Molecular Heparins market. At the same time biosimilar competition increased.

Fourth-quarter **Toujeo**<sup>®</sup> sales increased 13.9% to €272 million, due to strong growth in the Rest of the World region primarily driven by China reflecting increasing demand and a favorable basis for comparison. In Q4 2021, sales in China were impacted by price and inventory adjustment in anticipation of the Volume Based Procurement (VBP) for insulins. Sales in the U.S. were down 7.5% reflecting lower average price in the fourth quarter which more than offset volume growth.

**Plavix**<sup>®</sup> sales were up 11.7% in the fourth quarter at €245 million, reflecting consistent volume growth in China (sales up 21.6% to €108 million) which largely offset lower sales in Europe and also Japan where the product was impacted by a mandatory price cut at the beginning of April.

**Praluent**<sup>®</sup> fourth-quarter sales were €96 million, up 70.9%, driven by performance in Europe and an accelerated ramp-up in China due to the inclusion in the National Reimbursement Drug List (NRDL) effective January 2022.

<sup>2</sup> *EUROAPI third party sales were deconsolidated from May 10*

<sup>3</sup> *Sanofi has prioritized core assets in its General Medicines portfolio with differentiated and/or established profiles that have significant opportunity for growth in key markets.* 

------

**Multaq**<sup>®</sup> fourth-quarter sales decreased 6.1% to €104 million, reflecting a negative price effect in the U.S. despite higher volume.

Fourth-quarter **Soliqua**<sup>®</sup> sales were €55 million, down 5.6% due to lower sales in the U.S. which more than offset growth in the Rest of the World region. Soliqua<sup>®</sup> was approved in January in China and Sanofi will work with Chinese authorities to get access to patients through inclusion into the NRDL.

Sales of **Rezurock**<sup>®</sup> were €63 million in the fourth quarter. Since launch more than 1400 patients have been treated with Rezurock<sup>®</sup> (representing more than 30% of current addressable patient population) with strong persistency rates.

**Non-core assets** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Lantus<sup>®\*</sup> | 429 | *-27.6 %* | 2259 | *-14.4 %* |
| Aprovel<sup>®</sup>/Avapro<sup>®</sup> | 104 | *-9.8 %* | 478 | *+7.6 %* |
| Other non-core assets | 1071 | *-1.8 %* | 4485 | *-7.7 %* |
| **Total non-core assets** | **1604** | ***-10.8*** *%*** | **7222** | ***-9.0*** *%*** |

---

In the fourth quarter, **non-core assets sales** decreased 10.8% to €1,604 million reflecting divestments (-1.9 ppt), and lower sales of Lantus<sup>®</sup> in the U.S. In 2022, **non-core assets sales** decreased 9.0% (and 7.4% excluding divestments), reflecting VBP impact in China on Lantus<sup>®</sup>, Eloxatin<sup>®</sup> and Taxotere<sup>®</sup> sales as well as lower Lantus<sup>®</sup> sales in the U.S.

**Lantus**<sup>®</sup> sales were €429 million, down 27.6% in the fourth quarter. In the U.S., sales decreased 56.7%, impacted by prior formulary losses as well as by erosion of the basal insulin market. In Rest of the World region, sales were down 7.7% reflecting the insulin VBP in China starting in May this year.

In China, Sanofi participated in the VBP tender for basal insulin analogues in November 2021 and was among the bidding winners in Group A with Toujeo<sup>®</sup> and Lantus<sup>®</sup>. In China, fourth-quarter Toujeo<sup>®</sup> and Lantus<sup>®</sup> sales were €51 million (up 18.6%), mainly reflecting higher Toujeo<sup>®</sup> sales which benefited from growing demand and a favorable base of comparison due to price and inventory adjustment in the fourth quarter of 2021 in anticipation of the VBP. In 2022, Toujeo<sup>®</sup> and Lantus<sup>®</sup> sales were €447 million (down 10.7%), mainly reflecting lower Lantus<sup>®</sup> sales which benefitted from higher volumes at significantly lower prices.

Fourth-quarter **Aprovel**<sup>®</sup>**/Avapro**<sup>®</sup> sales were down 9.8% to €104 million mainly due to lower sales in the Rest of the World region.

**Pharmaceuticals business operating income**

In the fourth quarter, **business operating income** (BOI) of Pharmaceuticals increased 19.1% to €2,490 million (up 15.1% at CER). The ratio of BOI to net sales increased by 1.8 percentage point to 32.0% (32.4% at CER), reflecting an improvement of the gross margin ratio, moderate growth of SG&A expenses despite continued increase in R&D expenses. In 2022, business operating income of Pharmaceuticals increased 17.4% to €11,043 million (up 10.5% at CER). The ratio of BOI to net sales increased by 1.1 percentage point to 36.0% (36.0% at CER).

------

*Vaccines* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| Influenza vaccines<br>*(incl. Fluzone*<sup>®</sup> *HD/ Efluelda*<sup>®</sup>*, Fluzone*<sup>®</sup>*, Flublok*<sup>®</sup>*, Vaxigrip*<sup>®</sup>*)* | 802 | *-32.0 %* | 2977 | *+2.4 %* |
| Polio/Pertussis/Hib vaccines <br>*(incl. Hexaxim*<sup>®</sup> */ Hexyon*<sup>®</sup>*, Pentacel*<sup>®</sup>*, Pentaxim*<sup>®</sup> *and Imovax*<sup>®</sup>*)* | 443 | *-16.9 %* | 2285 | *+2.5 %* |
| Meningitis vaccines <br>*(incl. Menactra*<sup>®,</sup> *MenQuadfi*<sup>®</sup>*)* | 110 | *+14.3 %* | 703 | *-3.6 %* |
| Booster vaccines *(incl. Adacel* <sup>®</sup>*)* | 148 | *+12.1 %* | 587 | *+11.3 %* |
| Travel and endemic vaccines | 121 | *+28.6 %* | 510 | *+57.8 %* |
| Other vaccines | 92 | *+309.1%* | 167 | *+86.9%* |
| **Total Vaccines** | **1716** | ***-16.3*** *%*** | **7229** | ***+6.3*** *%*** |

---

Fourth-quarter **Vaccines** sales decreased 16.3% (to €1,716 million) mainly reflecting accelerated supply phasing of influenza vaccines between the third and the fourth quarter 2022. In 2022, Vaccines sales were up 6.3%, reflecting progressive recovery of Travel and Booster vaccines.

**Influenza vaccines** sales decreased 32.0% to €802 million in the fourth quarter and accounted for 30% of northern hemisphere sales in the second half of 2022 compared to 45% in the fourth quarter of 2021.

New manufacturing capacity in the U.S. allowing for a new record year for influenza vaccines sales. This was again driven by continuous conversion to differentiated premium priced vaccines such as Fluzone<sup>®</sup> HD in the U.S. and Efluelda<sup>®</sup> in Europe that have demonstrated improved efficacy against a standard dose vaccine in randomized controlled trials. Full-year 2022 influenza sales reached €2,977 million.

In the fourth quarter, **Polio/Pertussis/Hib** (PPH) vaccines sales decreased -16.9% to €443 million reflecting lower sales in the Rest of the World region due to unfavorable purchasing pattern. In addition, Pentaxim<sup>®</sup> sales in China decreased due to the COVID disruption. In the U.S. Vaxelis<sup>®</sup> continues to capture market share progressively replacing pentavalent vaccines in the primary series of infant immunization. As a reminder, Vaxelis<sup>®</sup> in-market sales are not consolidated and the profits are shared equally between Sanofi and Merck & co. Full-year 2022 PPH sales reached €2,285 million.

Fourth-quarter **Meningitis** sales increased 14.3% to €110 million, reflecting significant growth in the Rest of the World region. In the U.S., Meningitis sales benefited from favorable purchasing pattern.

**Booster** vaccines sales increased 12.1% in the fourth quarter to €148 million, driven by the Rest of the World region.

Fourth-quarter **Travel and endemic vaccines** sales increased 28.6% to €121 million, reflecting growth across all geographies in a post pandemic environment.

Sales of **Other Vaccines** were €92 million (up +309.1%) in the fourth quarter and included also sales of the recently approved monovalent recombinant-protein COVID-19 booster vaccine VidPrevtyn<sup>®</sup> Beta.

**Vaccines business operating income**

In the fourth quarter, **business operating income** (BOI) decreased 8.3% (down 13.6% at CER) to €599 million compared to the same period of last year, reflecting earlier time to market of flu vaccines sales, higher R&D expenses related to the mRNA center of excellence which were partially offset by the capital gain generated by the sale of the Japanese encephalitis vaccine, a non-core vaccine. BOI to net sales ratio was 34.9% (34.3% at CER) versus 33.2% in the fourth quarter of 2021.

In 2022, BOI of Vaccines increased 21.4% (up 9.8% at CER) to €3,168 million reflecting strong sales growth, gross margin improvement, moderate SG&A evolution despite higher R&D costs. The ratio of BOI to net sales was 43.8% (42.6% at CER) versus 41.3% in 2021.

------

*Consumer Healthcare*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net sales (€ million)** | **Q4 2022** | ***Change*** <br>***at CER*** | **2022** | ***Change*** <br>***at CER*** |
| Allergy | 156 | *+15.0 %* | 734 | *+10.5 %* |
| Cough & Cold | 132 | *+11.2 %* | 478 | *+46.3 %* |
| Pain Care | 303 | *+8.7 %* | 1213 | *+7.9 %* |
| Digestive Wellness | 306 | *+12.0 %* | 1318 | *+12.4 %* |
| Physical and Mental Wellness | 124 | *-8.5 %* | 562 | *+0.7%* |
| Personal Care | 157 | *+8.3 %* | 586 | *+2.3 %* |
| Non-Core / Others | 38 | *-29.1 %* | 189 | *-27.4 %* |
| **Total Consumer Healthcare** | **1216** | ***+6.6*** *%*** | **5080** | ***+8.6*** *%*** |

---

In the fourth quarter, **Consumer Healthcare** (CHC) sales increased 6.6% to €1,216 million driven by growth in all regions. This global performance includes a positive price effect of 4.7 percentage points (ppt). The divestments of non-core products had a negative impact of 0.9 ppt in the fourth quarter mainly impacting the Non-core/others category. (The CHC organic sales growth was 7.5% in the fourth quarter excluding divestments impact). In 2022, CHC sales increased 8.6% supported by double-digit growth in Europe and the Rest of the World region. In 2022, the divestments of non-core products had a negative impact of 1.0 ppt. (The CHC organic sales growth was 9.6% in 2022 excluding divestments impact).

In the **U.S.**, fourth-quarter CHC sales increased 3.9% to €326 million driven by Digestive Wellness and Personal Care categories.

In **Europe**, fourth-quarter CHC sales increased 8.7% to €371 million mainly reflecting double-digit growth of Cough & Cold season and Digestive Wellness categories.

In **Rest of World**, fourth-quarter CHC sales increased 6.6% to €519 million, supported by double-digit growth of Pain Care and Allergy categories.

**CHC business operating income**

In the fourth quarter, **business operating income** (BOI) of CHC increased 27.9% (up 25.5% at CER) to €381 million, driven by solid sales performance, moderate SG&A growth as well as higher capital gains related to divestments of non-strategic assets. The ratio of BOI to net sales increased 4.5 percentage points to 31.3% (31.6% at CER) versus the fourth quarter of 2021. In 2022, BOI of CHC increased 21.2% (up 15.8% at CER) to €1,810 million mainly driven by sales growth and higher capital gains related to divestments of non-strategic assets. The ratio of BOI to net sales increased 2.2 percentage points to 35.6% (35.6% at CER).

*Company sales by geographic region*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Sanofi sales (€ million)** | **Q4 2022** | ***Change <br>at CER*** | **2022** | ***Change <br>at CER*** |
| **United States** | **4671** | ***+8.7*** *%*** | **18275** | ***+12.2*** *%*** |
| **Europe** | **2636** | ***-5.6*** *%*** | **9999** | ***+2.4*** *%*** |
| **Rest of the World** | **3418** | ***+2.4*** *%*** | **14723** | ***+4.8*** *%*** |
| *of which China* | *578* | *+2.3 %* | *3123* | *+6.2%* |
| *of which Japan* | *406* | *+10.9 %* | *1613* | *+3.1 %* |
| *of which Brazil* | *204* | *+4.9 %* | *927* | *-2.0 %* |
| *of which Russia* | *172* | *-0.7 %* | *674* | *+0.7%* |
| **Total Sanofi sales** | **10725** | ***+2.6*** *%*** | **42997** | ***+7.0*** *%*** |

---

In the **U.S.,** fourth-quarter sales increased 8.7% (to €4,671 million), supported by the strong performance of Specialty Care driven by Dupixent<sup>®</sup>.

In **Europe,** fourth-quarter sales decreased 5.6% (to €2,636 million) reflecting lower flu vaccines sales and deconsolidation of Libtayo<sup>®</sup> sales, partially offset by Dupixent<sup>®</sup> and CHC performance.

In the **Rest of World region,** fourth-quarter sales increased 2.4% (to €3,418 million), reflecting the performance of Specialty Care driven by Dupixent<sup>®</sup>, growth of General Medicines core assets and CHC which largely offset lower Vaccines sales. Sales in **China** increased 2.3% to €578 million, driven by Dupixent<sup>®</sup>, Praluent<sup>®</sup>, Plavix<sup>®</sup> and Toujeo<sup>®</sup> which more than offset the VBP impact on Lantus<sup>®</sup> and lower Vaccines sales. In **Japan,** fourth-quarter sales increased 10.9% to €406 million mainly driven by the

------

growth of Dupixent<sup>®</sup>, Sarclisa<sup>®</sup> and CHC. In **Brazil**, fourth-quarter sales were up 4.9% driven by General Medicines core-assets. Full-year 2022 sales in Brazil were down 2.0% reflecting lower Vaccines and Lovenox<sup>®</sup> sales. In **Russia**, fourth-quarter sales decreased 0.7% to 172 million. In March 2022, Sanofi has stopped any new spending not related to the supply of its essential and life-changing medicines and vaccines in Russia. This includes all advertising and promotional spending.

------

*R&D update at the end of the fourth quarter 2022*

**Regulatory update** 

&nbsp;&nbsp;&nbsp;&nbsp;• The European Commission (EC) approved *Beyfortus*<sup>®</sup> (nirsevimab) for the prevention of **respiratory syncytial virus** (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two. Beyfortus<sup>®</sup> is the first and only single-dose RSV protective option for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. Beyfortus<sup>®</sup> was also granted approval in the United Kingdom.

&nbsp;&nbsp;&nbsp;&nbsp;• The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for *Beyfortus*<sup>®</sup> for the prevention of **respiratory syncytial virus** (RSV) lower respiratory tract disease in newborns and infants entering or during their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

&nbsp;&nbsp;&nbsp;&nbsp;• The EC expanded the marketing authorization for *Dupixent*<sup>®</sup> (dupilumab) in the European Union to treat adults with moderate-to-severe **prurigo nodularis** (PN) who are candidates for systemic therapy. With this approval, Dupixent<sup>®</sup> is the first and only targeted medicine specifically indicated to treat PN in Europe and the U.S.

&nbsp;&nbsp;&nbsp;&nbsp;• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for *Dupixent*<sup>®</sup>, recommending the approval in Europe, to treat adults and adolescents with **eosinophilic esophagitis** (EoE).

&nbsp;&nbsp;&nbsp;&nbsp;• *VidPrevtyn*<sup>®</sup> *Beta* was approved by the EC, as a booster for the **prevention of COVID-19** in adults who have previously received an mRNA or adenoviral COVID-19 vaccine. Designed to provide broad protection against multiple variants, the protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK's pandemic adjuvant.

&nbsp;&nbsp;&nbsp;&nbsp;• The EC granted marketing authorization for *Enjaymo*<sup>®</sup> (sutimlimab) for the treatment of adult patients with **cold agglutinin disease** (CAD), a rare, serious, and chronic autoimmune hemolytic anemia.

&nbsp;&nbsp;&nbsp;&nbsp;• Regeneron announced that the FDA approved *Libtayo*<sup>®</sup> (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced **non-small cell lung cancer** (NSCLC) with no EGFR, ALK or ROS1 aberrations.This approval triggered Sanofi receiving a $100 million regulatory milestone payment

**Portfolio update**

**Phase 3:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The *Dupixent*<sup>®</sup> Phase 3 results in adults and adolescents with **eosinophilic esophagitis** (EoE) were published in the New England Journal of Medicine. Dupixent is the first and only targeted medicine indicated in the U.S. to treat EoE patients aged 12 and older, weighing at least 40 kg.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The *tolebrutinib* Phase 3 trial in **nrSPMS** (non-relapsing secondary progressive multiple sclerosis, HERCULES) was fully recruited in December 2022. Non-relapsing SPMS is an area of highest unmet need in MS as no approved treatments are currently available. Sanofi continues to recruit in PERSEUS, the trial for **PPMS** (primary progressive MS), outside of the U.S.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The URSA study, a randomized, double blind, placebo-controlled trial evaluating the efficacy and safety of *tolebrutinib* in patients with moderate-to-severe **myasthenia gravis** (MG) was discontinued after careful evaluation of the emerging competitive treatment landscape in MG.

**Phase 2:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The study evaluating *eclitasertib* (RIPK1 inhibitor) in patients with **ulcerative colitis** (UC) enrolled its first participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sanofi decided to terminate its collaboration program with Revolution Medicines for the development of *SAR442720* (SHP2 inhibitor) for the treatment of **solid tumors**, following a pipeline review and reprioritization of projects.

**Phase 1:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The development program for *SAR444419* (anti-TNFa/IL-6 Nanobody<sup>®</sup> VHH) in **inflammatory indication** was initiated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The study evaluating *SAR444559*, an anti-CD38 mAb of next generation in **inflammatory indication** enrolled its first participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The study of the anti PD1/IL-15 fusion protein, *SAR445877* (formerly known as KD050, entering our pipeline through Kadmon acquisition) in patients with **solid tumors** enrolled its first participants.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The study evaluating the safety and tolerability of intravenous *SAR446159* (also known as ABL301), an anti-alpha-synuclein/IGF1R mAb in **Parkinson's Disease**, was initiated in collaboration with ABL Bio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The randomized, double-blind study evaluating the safety, tolerability, and activity of *SAR439459* (anti-TGFb mAb), for the treatment of **Osteogenesis Imperfecta**, was initiated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Three Phase 1/2 studies with different LNP formulations evaluating the safety and immunogenicity of *Quadrivalent Influenza mRNA vaccine* in adults, enrolled their first participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Phase 1/2 study evaluating the safety and immunogenicity of the *RSV mRNA vaccine in older adults*, formulated with 2 different LNPs, enrolled its first participants.

**Acquisitions and major collaborations**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sanofi and Innate Pharma announced an **expansion of their collaboration**, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKET<sup>TM</sup> (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET<sup>TM</sup> targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.

*An update of the R&D pipeline at as of Dec 31, 2022, is available on our website*: https://www.sanofi.com/en/science-and-innovation/research-and-development

------

*Corporate Social Responsibility update at the end of the fourth quarter 2022*

**Access to medicines**

**Positive Phase 2/3 results of acoziborole with the potential to further transform the treatment of sleeping sickness**

Sanofi has collaborated with the World Health Organization (WHO) since 2001, with the objective to contribute to eliminate sleeping sickness, or Human African Trypanosomiasis (HAT), by 2030.

Sleeping sickness is a neglected tropical disease, which affects mostly poor populations living in remote rural areas of sub-Saharan Africa. If left untreated, the parasitic disease is usually fatal. Since the start of Sanofi's collaboration with the WHO, the number of cases of sleeping sickness has fallen by 97%, from 26,950 in 2001 to 805 in 2021, dropping below 1,000 for the fourth consecutive year. Through Sanofi's partnership with the World Health Organization (WHO), the company supports disease management, including screening of populations, disease awareness campaign, capacity building, as well as drug donation.

In September 2020, Sanofi and the Drugs for Neglected Diseases initiative (DNDi) signed an agreement to develop and roll out acoziborole, a single dose treatment administered at the point of diagnosis making it a potential game-changer to support the sustainable elimination of the disease once approved. This new chemical entity has been tested in Phase 2/3 clinical studies in Democratic Republic of Congo and Guinea. The results, which were published in the Lancet Infectious Diseases medical journal in November 2022, showed that the 18-month treatment success rate for acoziborole was 95% in late-stage g-HAT patients. The study shows that acoziborole has a favorable safety profile, with no significant drug-related safety signals being reported.

Upon approval, acoziborole could replace fexinidazole, also developed by Sanofi and DNDi and first approved in 2018. Fexinidazole is a ten-day once-a-day treatment that is effective in both the first and the second stages of the disease in adults and children aged six years and older.

**Environment**

**Accelerating our ambition towards net zero emissions by 5 years, now targeting 2045**

Sanofi is accelerating its efforts to address climate change and now build the road to net zero emissions across all operations (scope 1 & 2) and the entire value chain (scope 3) by 2045. This is an acceleration of 5 years compared to Sanofi's previous commitment towards net zero emissions by 2050.

This new commitment will be building on years of work to reduce the environmental footprint of its products and activities. The progress of Sanofi's environmental strategy is disclosed in appendix 10: CSR dashboards.

**ESG ratings**

Sanofi has been recognized again on the 2022 CDP's Climate Change A List for its commitment and transparency in the fight against climate change. In addition, Sanofi has also achieved the leadership score (A-) for its actions to protect water resources.

Sanofi has also been awarded the 2022 Terra Carta Seal. The Seal is being awarded to companies from around the world who are driving innovation and leadership in their industry and tackling climate change. All recipients must have credible transition roadmaps underpinned by globally recognised, scientific metrics for achieving net zero by 2050 or earlier and have ambitions aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet.

Additionally, in recognition of Sanofi' continued CSR strategy implementation, a few of Sanofi's ESG rankings have been positively updated:

------

![esgratingsq4v2.jpg](esgratingsq4v2.jpg)

------

*Fourth-quarter and full-year 2022 financial results*

**Business Net Income**<sup>4</sup>

In the fourth quarter of 2022, Sanofi generated **net sales** of €10,725 million, an increase of 7.3% (up 2.6% at CER). Full-year 2022 net sales were €42,997 million up 13.9% (up 7.0% at CER).

Fourth-quarter **other revenues** increased 73.6% (up 58.2% at CER) to €731 million, including increased VaxServe sales of non-Sanofi products of €413 million (up 27.4% at CER). In 2022, other revenues increased 69.2% (up 51.9% at CER) to €2,392 million, including VaxServe sales of non-Sanofi products of €1,567 million (up 28.5% at CER).

Fourth-quarter **Gross Profit** increased 11.2% (up 5.4% at CER) to €7,722 million. The gross margin ratio increased 2.5 percentage point to 72.0% versus the same period of 2021, reflecting positive currency effect, improvement of the Pharmaceuticals gross margin ratio (which increased from 75.4% to 77.1%) driven by favorable product mix and efficiency gains and Vaccines gross margin ratio (58.9% from 56.0%), benefitting from a favorable comparison basis. CHC gross margin ratio increased 0.2 percentage point to 62.7%. In 2022, the gross margin ratio increased 2.4 percentage points to 73.7% (73.1% at CER) driven by Pharmaceuticals and Vaccines.

**Research and Development** (R&D) expenses were up 15.0% (up 10,1% at CER) to €1,823 million in the fourth quarter, reflecting increased expenses in pharmaceuticals priority assets and early-stage projects as well as in Vaccines. In 2022, R&D expenses increased 17.8% to €6,706 million (up 12.3% at CER).

Fourth-quarter **selling general and administrative expenses** (SG&A) increased 5.0% to €2,895 million. At CER, SG&A expenses were stable, reflecting efficiency measures which more than offset increased commercial investments in Specialty Care growth drivers. In the fourth quarter, the ratio of SG&A to sales decreased 0.6 percentage point to 27.0% compared to the prior year. In 2022, SG&A expenses increased 9.8% to €10,492 million (up 3.3% at CER) and the ratio of SG&A to sales was 0.9 percentage point lower at 24.4% compared to 2021.

Fourth-quarter and full-year 2022 **operating expenses** were €4,718 million, (up 8.6% and 3.7% at CER) and €17,198 million (up 12.8% and 6.6% at CER).

Fourth-quarter **other current operating income net of expenses** was €-276 million versus €-356 million in the fourth quarter of 2021. Other current operating income net of expenses included an expense of €659 million (versus an expense of €444 million in the fourth quarter of 2021) corresponding to the share of profit to Regeneron of the monoclonal antibodies Alliance, additional share of profit paid by Regeneron towards development costs (which increased from 10% to 20% from April 1<sup>st</sup>) and the reimbursement of commercialization-related expenses incurred by Regeneron. In the fourth quarter, this line also included €227 million of net capital gains related to portfolio streamlining compared to €61 million in the same period of 2021.

In 2022, other current operating income net of expenses was €-1,514 million versus €-946 million in 2021 and included €615 million of net capital gains related to portfolio streamlining compared to €318 million in 2021. In 2022 expense associated with the monoclonal antibodies Alliance with Regeneron was €2,367 million, which compared with an expense of €1,429 million in 2021 (see appendix 7 for further details).

The fourth-quarter and full-year **share of profit from associates** was €6 million and €88 million versus €18 million and €39 million in the same periods of 2021, respectively, and included the share of U.S. profit related to Vaxelis<sup>®</sup>.

Fourth-quarter **business operating income**<sup>4</sup> (BOI) increased 20.7% to €2,724 million. At CER, BOI increased 15.0%. The ratio of BOI to net sales increased 2.8 percentage points to 25.4%. In 2022, BOI was €13,040 million, up 21.7% (up 13.3% at CER). In 2022, the ratio of business operating income to net sales increased 1.9 percentage point to 30.3% (30.0% at CER).

**Net financial expenses** were €-28 million and €-234 million in the fourth quarter and full-year 2022, respectively, versus €-83 million and €-328 million in the same periods of 2021.

Fourth-quarter **effective tax rate** was 20,6% versus 20.5% in the same periods of 2021. Full-year 2022 effective tax rate was 19.3% versus 20.9% in 2021. Sanofi expects its effective tax rate to be around 19% in 2023.

Fourth-quarter **business net income**<sup>4</sup> increased 23.8% to €2,141 million and increased 17.6% at CER. The ratio of business net income to net sales increased 2.7 percentage points to 20.0% versus the fourth quarter of 2021. In 2022, business net income increased 25.9% to €10,341 million and increased 17.0%

<sup>4</sup>*See Appendix 3 for 2022 fourth-quarter consolidated income statement; see Appendix 9 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.* 

------

at CER. The ratio of business net income to net sales increased 2.4 percentage points to 24.1% versus 2021.

In the fourth quarter of 2022, **business earnings per share**<sup>4</sup> (EPS) was €1.71, up 23.9% on a reported basis (up 17,4% at CER). The average number of shares outstanding was 1,254.0 million versus 1,254.9 million in the fourth quarter of 2021. In 2022, business earnings per share<sup>8</sup> was €8.26, up 25.9% on a reported basis and up 17.1% at CER. The average number of shares outstanding was 1,251.9 million versus 1,252.5 million in 2021.

**Reconciliation of IFRS net income reported to business net income (see Appendix 4)** 

In 2022, the IFRS net income was €6,720 million. The main items excluded from the business net income were:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An amortization charge of €2,053 million related to fair value remeasurement on intangible assets of acquired companies (primarily Genzyme: €535 million, Bioverativ: €377 million, Boehringer Ingelheim CHC business: €188 million, Ablynx: €168 million and Kadmon €159 million) and to acquired intangible assets (licenses/products: €334 million). These items have no cash impact on the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An impairment of intangible assets of €1,700 million of which €1,586 million are related to SAR444245 recorded in the third quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An upfront payment of $900 million (€856 million) and a regulatory milestone payment of $100 million (€96 million) received by Sanofi from Regeneron following the restructuring of the Immuno-Oncology agreement and collaboration. These items are included in Consolidated income statements line *Other Operating Income* (see Appendix 7).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Restructuring costs and similar items of €1,336 million related to streamlining initiatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other gains and losses, and litigation charge of €370 million, mainly including costs related to major litigations (including the estimated future defense costs relating to the Zantac<sup>®</sup> litigation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A €962 million tax effect arising from the items listed above, mainly comprising €771 million of deferred taxes generated by amortization and impairments of intangible assets and €231 million associated with restructuring costs and similar items (see Appendix 4).

**Capital Allocation**

In 2022, free cash flow before restructuring, acquisitions and disposals decreased by 10.8% to €8,902 million, after net changes in working capital (€-477 million) and capital expenditures (€-1,594 million). After acquisitions<sup>5</sup> (€-824 million), proceeds from disposals<sup>5</sup> (€1,531 million) and payments related to restructuring and similar items (-€1,126 million), **free cash flow**<sup>6</sup> increased 4.8% to €8,483 million. After the acquisition of Amunix (-€875 million), the dividend paid by Sanofi (-€4,168 million), net debt decreased from €9,983 million at December 31, 2021 to €6,437 million at December 31, 2022 (amount net of €12,736 million cash and cash equivalents).

<sup>5</sup> *Not exceeding €500 million per transaction (inclusive of all payments related to the transaction).*

<sup>6</sup> *non-GAAP financial measure (definition in Appendix 9).*

------

***Forward-Looking Statements***

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

*Appendices*

---

| | |
|:---|:---|
| Appendix 1:  | Fourth-quarter and full-year 2022 sales by GBU, franchise, geographic region and product |
| [Appendix 2:](#i99a8229dc59741fa88b7606c304d7a60_133) | Fourth-quarterand full-year [2022 business net income statement](#i99a8229dc59741fa88b7606c304d7a60_133) |
| [Appendix 3:](#i99a8229dc59741fa88b7606c304d7a60_139) | Fourth-quarter and full-year [2022 consolidated income statement](#i99a8229dc59741fa88b7606c304d7a60_139) |
| [Appendix 4:](#i99a8229dc59741fa88b7606c304d7a60_142) | [Reconciliation of IFRS net income reported to business net income](#i99a8229dc59741fa88b7606c304d7a60_142) |
| [Appendix 5:](#i99a8229dc59741fa88b7606c304d7a60_145) | [Change in net debt](#i99a8229dc59741fa88b7606c304d7a60_145) |
| Appendix 6 | Simplified consolidated balance sheet |
| Appendix 7 | Other current operating income net of expenses – Regeneron Alliances |
| Appendix 8: | Currency sensitivity |
| [Appendix](#i99a8229dc59741fa88b7606c304d7a60_160)9: | [Definitions of non-GAAP financial indicators](#i99a8229dc59741fa88b7606c304d7a60_160) |
| Appendix 10: | CSR Dashboards |

---

*Media Relations*

**Sandrine Guendoul** \| + 33 6 25 09 14 25 \| sandrine.guendoul@sanofi.com

**Nicolas Obrist** \| + 33 6 77 21 27 55 \| nicolas.obrist@sanofi.com

**Victor Rouault** \| + 33 6 70 93 71 40 \| victor.rouault@sanofi.com

**Chrystel Baude** \| + 33 6 70 98 70 59 \| chrystel.baude@sanofi.com

**Sally Bain** \| + 1 617 834 6026 \| sally.bain@sanofi.com

**Evan Berland** \| +1 215 432 0234 \| evan.berland@sanofi.com

**Kate Conway** \| + 1 508 364 4931 \| <u>kate.conway@sanofi.com</u>

*Investor Relations*

**Eva Schaefer-Jansen** \| + 33 7 86 80 56 39 \| eva.schaefer-jansen@sanofi.com

**Arnaud Delépine** \| + 33 6 73 69 36 93 \| arnaud.delepine@sanofi.com

**Corentine Driancourt** \| + 33 6 40 56 92 21 \| corentine.driancourt@sanofi.com

**Felix Lauscher** \| + 1 908 612 7239 \| felix.lauscher@sanofi.com

**Nathalie Pham** \| + 33 7 85 93 30 17 \| nathalie.pham@sanofi.com

**Tarik Elgoutni**\| + 1 617 528 8427 \| Tarik.Elgoutni@sanofi.com

------

*Appendix 1: 2022 fourth-quarter and full-year net sales by GBU, franchise, geographic region and product*

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Q4 2022<br>(€ million)** | **Total Sales** | **% CER** | **% reported** | **United States** | **% CER** | **Europe** | **% CER** | **Rest of the world** | **% CER** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Dupixent** | **2402** | **+42.1%** | **+55.1%** | **1890** | **+43.8%** | **249** | **+33.2%** | **263** | **+40.1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aubagio | 493 | -4.6% | +3.1% | 357 | 0.0% | 123 | -1.6% | 13 | -58.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lemtrada | 17 | -15.8% | -10.5% | 5 | -16.7% | 5 | -16.7% | 7 | -14.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kevzara | 79 | -17.6% | -13.2% | 44 | +11.1% | 25 | -32.4% | 10 | -44.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Neurology & Immunology** | **589** | **-7.0%** | **+0.2%** | **406** | **+0.8%** | **153** | **-8.9%** | **30** | **-49.2%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cerezyme | 159 | -8.3% | -12.2% | 50 | -2.2% | 56 | -8.2% | 53 | -12.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cerdelga | 71 | +1.5% | +6.0% | 40 | 0.0% | 28 | 0.0% | 3 | +25.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Myozyme | 216 | -17.7% | -15.0% | 73 | -26.7% | 99 | -4.8% | 44 | -27.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nexviazyme | 65 | +306.7% | +333.3% | 49 | +214.3% | 8 | +800.0% | 8 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabrazyme | 240 | +3.6% | +7.6% | 123 | +4.8% | 58 | -1.7% | 59 | +6.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aldurazyme | 65 | +1.6% | +3.2% | 16 | -6.7% | 21 | 0.0% | 28 | +7.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Rare Disease** | **850** | **+1.8%** | **+3.9%** | **355** | **+4.6%** | **282** | **+3.3%** | **213** | **-3.3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jevtana | 87 | -24.5% | -20.9% | 59 | -25.4% | 7 | -58.8% | 21 | +4.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fasturtec | 47 | +7.3% | +14.6% | 31 | +12.0% | 12 | 0.0% | 4 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Libtayo |  | -100.0% | -100.0% |  | 0.0% | 1 | -100.0% | (1) | -100.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sarclisa | 86 | +55.6% | +59.3% | 35 | +52.4% | 27 | +30.0% | 24 | +100.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Oncology** | **221** | **-11.7%** | **-7.9%** | **125** | **-3.4%** | **47** | **-42.3%** | **49** | **+20.0%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alprolix | 141 | +14.2% | +24.8% | 101 | +3.4% |  | 0.0% | 40 | +50.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eloctate | 138 | -9.2% | -2.1% | 97 | -14.7% |  | 0.0% | 41 | +5.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cablivi | 62 | +52.6% | +63.2% | 36 | +73.7% | 22 | +21.1% | 4 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Rare Blood Disorder** | **352** | **+11.3%** | **+20.5%** | **241** | **+4.3%** | **22** | **+21.1%** | **89** | **+30.8%** |
| &nbsp;&nbsp;**Specialty Care** | **4414** | **+18.1%** | **+26.6%** | **3017** | **+24.8%** | **753** | **+3.7%** | **644** | **+11.5%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lovenox | 289 | -13.1% | -13.7% | 3 | -40.0% | 154 | -8.3% | 132 | -17.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Toujeo | 272 | +13.9% | +18.3% | 69 | -7.5% | 106 | +3.9% | 97 | +55.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plavix | 245 | +11.7% | +10.4% | 2 | 0.0% | 25 | -7.4% | 218 | +14.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multaq | 104 | -6.1% | +5.1% | 94 | -6.7% | 3 | -40.0% | 7 | +50.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thymoglobulin | 118 | +26.4% | +35.6% | 76 | +25.9% | 9 | 0.0% | 33 | +37.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mozobil | 69 | +3.2% | +9.5% | 41 | +2.8% | 18 | +20.0% | 10 | -16.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Praluent | 96 | +70.9% | +74.5% |  | 0.0% | 65 | +46.7% | 31 | +180.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliqua/iGlarLixi | 55 | -5.6% | +1.9% | 30 | -15.6% | 7 | -12.5% | 18 | +21.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rezurock | 63 | +180.0% | +215.0% | 63 | +180.0% | 1 | 0.0% | (1) | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Others core assets | 287 | +3.4% | +8.7% | 62 | -21.1% | 94 | +1.1% | 131 | +23.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Core Assets** | **1598** | **+8.0%** | **+11.8%** | **440** | **+4.8%** | **482** | **+2.3%** | **676** | **+14.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lantus | 429 | -27.6% | -26.4% | 115 | -56.7% | 104 | -9.6% | 210 | -7.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aprovel | 104 | -9.8% | -7.1% | 2 | -33.3% | 20 | -4.8% | 82 | -10.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Others non-core assets | 1071 | -1.8% | -1.6% | 112 | -15.9% | 269 | -12.2% | 690 | +5.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Non-Core Assets** | **1604** | **-10.8%** | **-10.0%** | **229** | **-43.3%** | **393** | **-11.2%** | **982** | **+0.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Industrial Sales** | **177** | **-22.7%** | **-19.5%** | **2** | **-75.0%** | **171** | **-18.3%** | **4** | **-70.0%** |
| &nbsp;&nbsp;**General Medicines** | **3379** | **-3.7%** | **-1.5%** | **671** | **-18.9%** | **1046** | **-6.8%** | **1662** | **+5.5%** |
| &nbsp;&nbsp;**Pharmaceuticals** | **7793** | **+7.3%** | **+12.6%** | **3688** | **+13.7%** | **1799** | **-2.6%** | **2306** | **+7.2%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Polio / Pertussis / Hib | 443 | -16.9% | -18.4% | 80 | -31.4% | 80 | -1.2% | 283 | -16.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Booster Vaccines | 148 | +12.1% | +19.4% | 73 | +6.6% | 39 | -11.4% | 36 | +84.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meningitis | 110 | +14.3% | +20.9% | 54 | -24.2% | 5 | 0.0% | 51 | +79.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Influenza Vaccines | 802 | -32.0% | -26.6% | 404 | -9.6% | 248 | -46.6% | 150 | -39.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Travel and Endemic Vaccines | 121 | +28.6% | +33.0% | 28 | +62.5% | 24 | +47.1% | 69 | +13.8% |
| &nbsp;&nbsp;**Vaccines** | **1716** | **-16.3%** | **-12.6%** | **657** | **-11.6%** | **466** | **-22.9%** | **593** | **-15.0%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allergy | 156 | +15.0% | +22.8% | 91 | +2.5% | 7 | 0.0% | 58 | +41.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cough and Cold | 132 | +11.2% | +13.8% |  | 0.0% | 74 | +15.4% | 58 | +5.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pain Care | 303 | +8.7% | +10.2% | 56 | -3.8% | 141 | +3.6% | 106 | +24.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Digestive Wellness | 306 | +12.0% | +10.9% | 45 | +20.6% | 107 | +18.5% | 154 | +6.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Physical Wellness | 69 | -15.2% | -12.7% |  | 0.0% | 7 | -22.2% | 62 | -14.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mental Wellness | 55 | +2.0% | +7.8% | 14 | 0.0% | 22 | 0.0% | 19 | +5.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personal Care | 157 | +8.3% | +18.9% | 126 | +10.8% |  | -100.0% | 31 | +3.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Core / Others | 38 | -29.1% | -30.9% | (6) | -700.0% | 13 | +9.1% | 31 | -23.3% |
| &nbsp;&nbsp;**Consumer Healthcare** | **1216** | **+6.6%** | **+9.5%** | **326** | **+3.9%** | **371** | **+8.7%** | **519** | **+6.6%** |
| &nbsp;&nbsp;**Company** | **10725** | **+2.6%** | **+7.3%** | **4671** | **+8.7%** | **2636** | **-5.6%** | **3418** | **+2.4%** |

---

------

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **2022<br>(€ million)** | **Total Sales** | **% CER** | **% reported** | **United States** | **% CER** | **Europe** | **% CER** | **Rest of the world** | **% CER** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Dupixent** | **8293** | **+43.8%** | **+58.0%** | **6346** | **+41.6%** | **940** | **+44.4%** | **1007** | **+56.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aubagio | 2031 | -4.3% | +3.9% | 1420 | -3.8% | 511 | 0.0% | 100 | -26.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lemtrada | 80 | -8.5% | -2.4% | 31 | -20.0% | 22 | -8.3% | 27 | +8.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kevzara | 339 | +11.8% | +18.1% | 186 | +23.0% | 106 | +2.9% | 47 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Neurology & Immunology** | **2450** | **-2.5%** | **+5.4%** | **1637** | **-1.8%** | **639** | **+0.2%** | **174** | **-15.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cerezyme | 707 | +2.6% | +3.5% | 194 | -0.6% | 239 | -2.0% | 274 | +9.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cerdelga | 288 | +6.7% | +13.4% | 160 | +7.6% | 111 | +5.7% | 17 | +5.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Myozyme | 958 | -8.8% | -4.5% | 318 | -24.1% | 408 | -0.5% | 232 | +1.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nexviazyme | 196 | +952.9% | +1052.9% | 158 | +833.3% | 17 | +750.0% | 21 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabrazyme | 938 | +5.2% | +11.1% | 471 | +5.8% | 228 | +2.2% | 239 | +7.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aldurazyme | 267 | +6.6% | +9.9% | 61 | 0.0% | 86 | +2.4% | 120 | +13.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Rare Disease** | **3445** | **+5.7%** | **+10.2%** | **1367** | **+6.3%** | **1104** | **+3.3%** | **974** | **+7.8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jevtana | 391 | -20.0% | -14.1% | 275 | -3.2% | 33 | -70.5% | 83 | -4.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fasturtec | 177 | +8.6% | +16.4% | 113 | +12.2% | 48 | +4.3% | 16 | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Libtayo | 88 | -34.1% | -31.8% |  | 0.0% | 70 | -34.3% | 18 | -33.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sarclisa | 294 | +60.2% | +67.0% | 127 | +68.7% | 88 | +35.9% | 79 | +82.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Oncology** | **952** | **-1.5%** | **+4.4%** | **515** | **+12.0%** | **239** | **-27.5%** | **198** | **+15.4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alprolix | 504 | +10.4% | +21.7% | 406 | +8.7% |  | 0.0% | 98 | +17.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eloctate | 580 | -5.9% | +3.0% | 450 | -6.8% |  | 0.0% | 130 | -3.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cablivi | 211 | +20.7% | +28.7% | 110 | +21.0% | 94 | +16.0% | 7 | +200.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Rare Blood Disorder** | **1317** | **+5.6%** | **+15.4%** | **983** | **+3.8%** | **94** | **+16.0%** | **240** | **+8.7%** |
| &nbsp;&nbsp;**Specialty Care** | **16457** | **+19.4%** | **+29.1%** | **10848** | **+22.7%** | **3016** | **+8.9%** | **2593** | **+20.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lovenox | 1310 | -13.8% | -11.8% | 17 | -48.3% | 658 | -5.8% | 635 | -19.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Toujeo | 1117 | +9.8% | +15.3% | 283 | -3.1% | 421 | +7.1% | 413 | +23.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plavix | 983 | +2.5% | +5.8% | 9 | -11.1% | 101 | -12.2% | 873 | +4.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multaq | 383 | +4.3% | +16.4% | 347 | +5.5% | 16 | -27.3% | 20 | +26.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thymoglobulin | 446 | +16.9% | +27.4% | 269 | +15.5% | 34 | 0.0% | 143 | +24.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mozobil | 261 | +4.3% | +12.0% | 154 | +6.2% | 67 | +11.7% | 40 | -11.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Praluent | 376 | +65.1% | +72.5% | 55 | +860.0% | 229 | +41.6% | 92 | +61.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliqua/iGlarLixi | 215 | +1.5% | +10.3% | 119 | -7.8% | 29 | 0.0% | 67 | +23.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rezurock | 207 | +815.0% | +935.0% | 206 | +815.0% | 1 | 0.0% |  | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Others core assets | 1091 | -0.2% | +5.0% | 194 | -30.8% | 361 | +3.4% | 536 | +14.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Core Assets** | **6389** | **+5.2%** | **+10.8%** | **1653** | **+11.6%** | **1917** | **+2.9%** | **2819** | **+3.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lantus | 2259 | -14.4% | -9.4% | 757 | -22.1% | 426 | -10.1% | 1076 | -10.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aprovel | 478 | +7.6% | +14.1% | 7 | -40.0% | 82 | -5.7% | 389 | +12.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Others non-core assets | 4485 | -7.7% | -5.2% | 412 | -10.7% | 1129 | -11.6% | 2944 | -5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Non-Core Assets** | **7222** | **-9.0%** | **-5.5%** | **1176** | **-18.6%** | **1637** | **-10.9%** | **4409** | **-5.5%** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Industrial Sales** | **620** | **-26.2%** | **-23.3%** | **17** | **-63.4%** | **587** | **-21.9%** | **16** | **-63.6%** |
| &nbsp;&nbsp;**General Medicines** | **14231** | **-4.2%** | **+0.1%** | **2846** | **-4.2%** | **4141** | **-6.9%** | **7244** | **-2.5%** |
| &nbsp;&nbsp;**Pharmaceuticals** | **30688** | **+6.9%** | **+13.8%** | **13694** | **+15.9%** | **7157** | **-0.8%** | **9837** | **+2.8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Polio / Pertussis / Hib | 2285 | +2.5% | +5.8% | 456 | -13.8% | 325 | +6.9% | 1504 | +7.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Booster Vaccines | 587 | +11.3% | +20.3% | 330 | +4.3% | 154 | +5.5% | 103 | +55.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meningitis | 703 | -3.6% | +6.8% | 531 | -4.9% | 15 | +1400.0% | 157 | -8.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Influenza Vaccines | 2977 | +2.4% | +13.3% | 1737 | +8.2% | 681 | -6.4% | 559 | -0.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Travel and Endemic Vaccines | 510 | +57.8% | +66.7% | 153 | +57.0% | 94 | +123.8% | 263 | +42.7% |
| &nbsp;&nbsp;**Vaccines** | **7229** | **+6.3%** | **+14.3%** | **3291** | **+3.0%** | **1341** | **+9.7%** | **2597** | **+8.4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allergy | 734 | +10.5% | +19.9% | 439 | +5.7% | 55 | +10.2% | 240 | +19.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cough and Cold | 478 | +46.3% | +49.4% |  | 0.0% | 263 | +69.2% | 215 | +24.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pain Care | 1213 | +7.9% | +11.0% | 212 | -4.1% | 555 | +8.3% | 446 | +13.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Digestive Wellness | 1318 | +12.4% | +16.5% | 144 | +3.2% | 432 | +11.3% | 742 | +14.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Physical Wellness | 324 | -3.7% | +0.3% |  | 0.0% | 23 | -20.7% | 301 | -2.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mental Wellness | 238 | +7.6% | +12.8% | 51 | -2.2% | 107 | +8.0% | 80 | +13.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personal Care | 586 | +2.3% | +12.9% | 453 | +2.3% | 1 | -75.0% | 132 | +5.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Core / Others | 189 | -27.4% | -27.0% | (9) | -200.0% | 65 | -27.5% | 133 | -18.8% |
| &nbsp;&nbsp;**Consumer Healthcare** | **5080** | **+8.6%** | **+13.7%** | **1290** | **+0.8%** | **1501** | **+13.1%** | **2289** | **+10.0%** |
| &nbsp;&nbsp;**Company** | **42997** | **+7.0%** | **+13.9%** | **18275** | **+12.2%** | **9999** | **+2.4%** | **14723** | **+4.8%** |

---

------

*Appendix 2: Business net income statement*

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fourth quarter 2022** | **Pharmaceuticals** | **Pharmaceuticals** | **Pharmaceuticals** | **Vaccines** | **Vaccines** | **Vaccines** | **Consumer Healthcare** | **Consumer Healthcare** | **Consumer Healthcare** | **Other**<sup>(1)</sup> | **Other**<sup>(1)</sup> | **Other**<sup>(1)</sup> | **Total Group** | **Total Group** | **Total Group** |
| **€ million** | **Q4 2022** | **Q4 2021** | *Change* | **Q4 2022** | **Q4 2021** | *Change* | **Q4 2022** | **Q4 2021** | *Change* | **Q4 2022** | **Q4 2021** | *Change* | **Q4 2022** | **Q4 2021** | *Change* |
| **Net sales** | **7793** | **6919** | ***12.6%*** | **1716** | **1964** | ***-12.6%*** | **1216** | **1111** | ***9.5%*** | **—** | **—** | **—%** | **10725** | **9994** | ***7.3%*** |
| Other revenues | 232 | 112 | *107.1%* | 479 | 295 | *62.4%* | 16 | 14 | *14.3%* | 4 |  | *—%* | 731 | 421 | *73.6%* |
| Cost of Sales | (2015) | (1817) | *10.9%* | (1184) | (1159) | *2.2%* | (469) | (431) | *8.8%* | (66) | (64) | *3.1%* | (3734) | (3471) | *7.6%* |
| *As % of net sales* | *(25.9)%* | *(26.3)%* |  | *(69.0)%* | *(59.0)%* |  | *(38.6)%* | *(38.8)%* |  |  |  |  | *(34.8)%* | *(34.7)%* |  |
| **Gross Profit** | **6010** | **5214** | ***15.3%*** | **1011** | **1100** | ***-8.1%*** | **763** | **694** | ***9.9%*** | **(62)** | **(64)** | ***-3.1%*** | **7722** | **6944** | ***11.2%*** |
| ***As % of net sales*** | ***77.1%*** | ***75.4%*** |  | ***58.9%*** | ***56.0%*** |  | ***62.7%*** | ***62.5%*** |  |  |  |  | ***72.0%*** | ***69.5%*** |  |
| Research and development expenses | (1328) | (1185) | *12.1%* | (264) | (210) | *25.7%* | (56) | (49) | *14.3%* | (175) | (141) | *24.1%* | (1823) | (1585) | *15.0%* |
| *As % of net sales* | *(17.0)%* | *(17.1)%* |  | *(15.4)%* | *(10.7)%* |  | *(4.6)%* | *(4.4)%* |  |  |  |  | *(17.0)%* | *(15.9)%* |  |
| Selling and general expenses | (1677) | (1565) | *7.2%* | (272) | (248) | *9.7%* | (367) | (361) | *1.7%* | (579) | (584) | *-0.9%* | (2895) | (2758) | *5.0%* |
| *As % of net sales* | *(21.5)%* | *(22.6)%* |  | *(15.9)%* | *(12.6)%* |  | *(30.2)%* | *(32.5)%* |  |  |  |  | *(27.0)%* | *(27.6)%* |  |
| Other current operating income/expenses | (506) | (376) |  | 121 | 5 |  | 39 | 11 |  | 70 | 4 |  | (276) | (356) |  |
| Share of profit/loss of associates\* and joint ventures |  | 9 |  | 3 | 6 |  | 3 | 3 |  |  |  |  | 6 | 18 |  |
| Net income attributable to non controlling interests | (9) | (6) |  |  |  |  | (1) |  |  |  | (1) |  | (10) | (7) |  |
| **Business operating income** | **2490** | **2091** | ***19.1%*** | **599** | **653** | ***-8.3%*** | **381** | **298** | ***27.9%*** | **(746)** | **(786)** | ***-5.1%*** | **2724** | **2256** | ***20.7%*** |
| ***As % of net sales*** | ***32.0%*** | ***30.2%*** |  | ***34.9%*** | ***33.2%*** |  | ***31.3%*** | ***26.8%*** |  |  |  |  | ***25.4%*** | ***22.6%*** |  |
|  |  |  |  | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | (28) | (83) |  |
|  |  |  |  | Income tax expenses | Income tax expenses | Income tax expenses |  |  |  |  |  |  | (555) | (443) |  |
|  |  |  |  | *Tax rate\*\** | *Tax rate\*\** | *Tax rate\*\** |  |  |  |  |  |  | *20,6%* | *20,5%* |  |
|  |  |  |  | **Business net income** | **Business net income** | **Business net income** |  |  |  |  |  |  | **2141** | **1730** | ***23.8%*** |
|  |  |  |  | ***As % of net sales*** | ***As % of net sales*** | ***As % of net sales*** |  |  |  |  |  |  | ***20.0%*** | ***17.3%*** |  |
|  |  |  |  | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **1.71** | **1.38** | ***23.9%*** |

---

*\* Net of tax.&nbsp;&nbsp;&nbsp;&nbsp;*

*\*\* Determined on the basis of Business income before tax, associates, and non-controlling interests.*

*\*\*\* Based on an average number of shares outstanding of 1,254.0 million in the fourth quarter of 2022 and 1,254.9 million in the fourth quarter of 2021.*

*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*

<sup>(1)</sup> *Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc…).*

------

*Appendix 2: Business net income statement*

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Full Year 2022** | **Pharmaceuticals** | **Pharmaceuticals** | **Pharmaceuticals** | **Vaccines** | **Vaccines** | **Vaccines** | **Consumer Healthcare** | **Consumer Healthcare** | **Consumer Healthcare** | **Other**<sup>(1)</sup> | **Other**<sup>(1)</sup> | **Other**<sup>(1)</sup> | **Total Group** | **Total Group** | **Total Group** |
| **€ million** | **FY 2022** | **FY 2021** | *Change* | **FY 2022** | **FY 2021** | *Change* | **FY 2022** | **FY 2021** | *Change* | **FY 2022** | **FY 2021** | *Change* | **FY 2022** | **FY 2021** | *Change* |
| **Net sales** | **30688** | **26970** | ***13.8%*** | **7229** | **6323** | ***14.3%*** | **5080** | **4468** | ***13.7%*** | **—** | **—** | **—%** | **42997** | **37761** | ***13.9%*** |
| Other revenues | 657 | 264 | *148.9%* | 1666 | 1095 | *52.1%* | 62 | 55 | *12.7%* | 7 |  | *—%* | 2392 | 1414 | *69.2%* |
| Cost of Sales | (7511) | (6965) | *7.8%* | (4101) | (3430) | *19.6%* | (1827) | (1606) | *13.8%* | (253) | (250) | *1.2%* | (13692) | (12251) | *11.8%* |
| *As % of net sales* | *(24.5)%* | *(25.8)%* |  | *(56.7)%* | *(54.2)%* |  | *(36.0)%* | *(35.9)%* |  |  |  |  | *(31.8)%* | *(32.4)%* |  |
| **Gross Profit** | **23834** | **20269** | ***17.6%*** | **4794** | **3988** | ***20.2%*** | **3315** | **2917** | ***13.6%*** | **(246)** | **(250)** | ***-1.6%*** | **31697** | **26924** | ***17.7%*** |
| ***As % of net sales*** | ***77.7%*** | ***75.2%*** |  | ***66.3%*** | ***63.1%*** |  | ***65.3%*** | ***65.3%*** |  |  |  |  | ***73.7%*** | ***71.3%*** |  |
| Research and development expenses | (5067) | (4330) | *17.0%* | (936) | (712) | *31.5%* | (187) | (153) | *22.2%* | (516) | (497) | *3.8%* | (6706) | (5692) | *17.8%* |
| *As % of net sales* | *(16.5)%* | *(16.1)%* |  | *(12.9)%* | *(11.3)%* |  | *(3.7)%* | *(3.4)%* |  |  |  |  | *(15.6)%* | *(15.1)%* |  |
| Selling and general expenses | (5923) | (5326) | *11.2%* | (870) | (805) | *8.1%* | (1478) | (1388) | *6.5%* | (2221) | (2036) | *9.1%* | (10492) | (9555) | *9.8%* |
| *As % of net sales* | *(19.3)%* | *(19.7)%* |  | *(12.0)%* | *(12.7)%* |  | *(29.1)%* | *(31.1)%* |  |  |  |  | *(24.4)%* | *(25.3)%* |  |
| Other current operating income/expenses | (1800) | (1172) |  | 132 | 128 |  | 152 | 111 |  | 2 | (13) |  | (1514) | (946) |  |
| Share of profit/loss of associates\* and joint ventures | 28 | 17 |  | 48 | 11 |  | 12 | 11 |  |  |  |  | 88 | 39 |  |
| Net income attributable to non controlling interests | (29) | (49) |  |  | (1) |  | (4) | (5) |  |  | (1) |  | (33) | (56) |  |
| **Business operating income**  | **11043** | **9409** | ***17.4%*** | **3168** | **2609** | ***21.4%*** | **1810** | **1493** | ***21.2%*** | **(2981)** | **(2797)** | ***6.6%*** | **13040** | **10714** | ***21.7%*** |
| ***As % of net sales*** | ***36.0%*** | ***34.9%*** |  | ***43.8%*** | ***41.3%*** |  | ***35.6%*** | ***33.4%*** |  |  |  |  | ***30.3%*** | ***28.4%*** |  |
|  |  |  |  |  |  |  | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | Financial income and expenses | (234) | (328) |  |
|  |  |  |  |  |  |  | Income tax expenses | Income tax expenses | Income tax expenses |  |  |  | (2465) | (2173) |  |
|  |  |  |  |  |  |  | *Tax rate\*\** | *Tax rate\*\** | *Tax rate\*\** |  |  |  | *19.3%* | *20.9%* |  |
|  |  |  |  |  |  |  | **Business net income** | **Business net income** | **Business net income** |  |  |  | **10341** | **8213** | ***25.9%*** |
|  |  |  |  |  |  |  | ***As % of net sales*** | ***As % of net sales*** | ***As % of net sales*** |  |  |  | ***24.1%*** | ***21.7%*** |  |
|  |  |  |  |  |  |  | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **Business earnings / share(in euros)\*\*\*** | **8.26** | **6.56** | ***25.9%*** |

---

 *\* Net of tax.&nbsp;&nbsp;&nbsp;&nbsp;*

*\*\* Determined on the basis of Business income before tax, associates, and non-controlling interests.*

*\*\*\* Based on an average number of shares outstanding of 1,251.9 million in the full year of 2022 and 1,252.5 million in the full year of 2021.*

*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*

<sup>(1)</sup> *Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc…).*

------

*Appendix 3: Consolidated income statements*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **€ million** | **Q4 2022** | **Q4 2021** | **FY 2022** | **FY 2021** |
| **Net sales** | **10725** | **9994** | **42997** | **37761** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other revenues | 731 | 421 | 2392 | 1414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | (3734) | (3475) | (13695) | (12255) |
| **Gross profit** | **7722** | **6940** | **31694** | **26920** |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | (1823) | (1585) | (6706) | (5692) |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling and general expenses | (2895) | (2758) | (10492) | (9555) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating income | 778 | 192 | 2403 | 859 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating expenses | (958) | (548) | (2965) | (1805) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | (457) | (420) | (2053) | (1580) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets | (27) | (15) | (1700) | (192) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value remeasurement of contingent consideration | 12 | (5) | 27 | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs and similar items | (170) | (326) | (1336) | (820) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other gains and losses, and litigation | (233) | (1) | (370) | (5) |
| **Operating income** | **1949** | **1474** | **8502** | **8126** |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial expenses | (148) | (93) | (440) | (368) |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial income | 120 | 10 | 206 | 40 |
| **Income before tax and associates and joint ventures** | **1921** | **1391** | **8268** | **7798** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | (407) | (268) | (1503) | (1558) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share of profit/(loss) of associates and joint ventures | 3 | 18 | 68 | 39 |
| **Net income** | **1517** | **1141** | **6833** | **6279** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to non-controlling interests | 57 | 10 | 113 | 56 |
| **Net income attributable to equity holders of Sanofi** | **1460** | **1131** | **6720** | **6223** |
| Average number of shares outstanding (million) | 1254.0 | 1254.9 | 1251.9 | 1252.5 |
| **IFRS Earnings per share (in euros)** | **1.16** | **0.90** | **5.37** | **4.97** |

---

------

*Appendix 4: Reconciliation of Net income attributable to equity holders of Sanofi to Business net income*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **€ million** | **Q4 2022** | **Q4 2021** | **FY 2022** | **FY 2021** |
| **Net income attributable to equity holders of Sanofi** | **1460** | **1131** | **6720** | **6223** |
| Amortization of intangible assets <sup>(1)</sup> | 457 | 420 | 2053 | 1580 |
| Impairment of intangible assets <sup>(2)</sup> | 27 | 15 | 1700 | 192 |
| Fair value remeasurement of contingent consideration <sup>(3)</sup> | 35 | 5 | 53 | 4 |
| Expenses arising from the impact of acquisitions on inventories |  | 4 | 3 | 4 |
| Income resulting from license-out <sup>(4)</sup> | (96) |  | (952) |  |
| Restructuring costs and similar items | 170 | 326 | 1336 | 820 |
| Other gains and losses, and litigation  | 233 | 1 | 370 | 5 |
| Tax effect of the items listed above: | (148) | (174) | (962) | (614) |
| &nbsp;&nbsp;&nbsp;*Amortization and impairment of intangible assets* | *(143)* | *(95)* | *(771)* | *(415)* |
| &nbsp;&nbsp;&nbsp;*Fair value remeasurement of contingent consideration* | *2* | *(4)* | *(9)* | *(2)* |
| &nbsp;&nbsp;&nbsp;*Restructuring costs and similar items* | *(30)* | *(79)* | *(231)* | *(200)* |
| &nbsp;&nbsp;&nbsp;*Other tax effects* | *23* | *4* | *49* | *3* |
| Other items | 3 | 2 | 20 | (1) |
| **Business net income** | **2141** | **1730** | **10341** | **8213** |
| **IFRS earnings per share** <sup>(5)</sup> **(in euros)** | **1.16** | **0.90** | **5.37** | **4.97** |

---

*(1)Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €430 million in the fourth quarter of 2022 and €397 million in the fourth quarter of 2021.*

*(2)In Q3 2022, impairment of €1,586 million related to SAR'245 Non-alpha IL2.*

*(3)In 2022, including non-controlling interest impact of €(80) million resulting from fair value adjustment of a contingent consideration in a subsidiary*

*(4)Upfront payment of $900 million (Q3 2022) and, regulatory milestone of 100m$(Q4 2022) in connection with Libtayo license-out reported in the Consolidated income statements line Other Operating Income.* 

*(5)Q4: Based on an average number of shares outstanding of 1,254.0 million in the fourth quarter of 2022 and 1,254.9 million in the fourth quarter of 2021.*

 *&nbsp;&nbsp;&nbsp;&nbsp;FY: Based on an average number of shares outstanding of 1,251.9 million in the full year of 2022 and 1,252.5 million in the full year of 2021.*

------

*Appendix 5: Change in net debt*

---

| | | |
|:---|:---|:---|
| **€ million** | **FY 2022** | **FY 2021** |
| **Business net income** | **10341** | **8213** |
| Depreciation & amortization & impairment of property, plant and equipment and software | 1587 | 1469 |
| Other items | (955) | 220 |
| **Operating cash flow** | **10973** | **9902** |
| Changes in Working Capital | (477) | 1475 |
| Acquisitions of property, plant and equipment and software | (1594) | (1400) |
| **Free cash flow before restructuring, acquisitions and disposals** | **8902** | **9977** |
| Acquisitions of intangibles assets, investments and other long-term financial assets <sup>(1)</sup> | (824) | (1488) |
| Restructuring costs and similar items paid | (1126) | (1060) |
| Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes <sup>(1)</sup> | 1531 | 667 |
| **Free cash flow** | **8483** | **8096** |
| Acquisitions of investments in consolidated undertakings including<br>assumed debt <sup>(2)</sup> | (1192) | (5298) |
| Proceeds from disposals of assets net of taxes <sup>(2)</sup> | 101 |  |
| Issuance of Sanofi shares | 188 | 186 |
| Acquisition of treasury shares | (497) | (382) |
| Dividends paid to shareholders of Sanofi | (4168) | (4008) |
| Other items <sup>(3)</sup> | 631 | 213 |
| **Change in net debt** | **3546** | **(1193)** |
| **Beginning of period** | **9983** | **8790** |
| **Closing of net debt** | **6437** | **9983** |

---

*(1)Free cash flow includes investments and divestments not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction).*

*(2)Includes transactions that are above a cap of €500 million per transaction (inclusive of all payments related to the transaction).*

*(3)In 2022, includes upfront payment of $900 million and regulatory milestone of $100 million received as part of Libtayo*<sup>®</sup> *license-out.*

------

*Appendix 6: Simplified consolidated balance sheet*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Assets (€ million)** | **December 31, 2022** | **December 31, 2021** | **Liabilities & equity (€ million)** | **December 31, 2022** | **December 31, 2021** |
|  |  |  | Equity attributable to equity holders of Sanofi | **73144** | 68681 |
|  |  |  | Equity attributable to non-controlling interests | 368 | 350 |
|  |  |  | **Total equity** | **73512** | **69031** |
|  |  |  | Long-term debt | 14857 | 17123 |
| Property, plant and equipment - Owned Assets | 9869 | 10028 | Non-current lease liabilities | 1904 | 1839 |
| Right-of-use assets | 1815 | 1948 | Non-current liabilities related to business combinations and to non-controlling interests | 674 | 577 |
| Intangible assets (including goodwill) | 69395 | 69463 | Non-current provisions and other non-current liabilities | 6341 | 6721 |
| Non-current income tax assets | 242 | 175 | Non-current income tax liabilities | 1979 | 2039 |
| Non-current financial assets & investments in associates and deferred tax assets | 9153 | 7975 | Deferred tax liabilities | 1344 | 1617 |
| **Non-current assets** | **90474** | **89589** | **Non-current liabilities** | **27099** | **29916** |
|  |  |  | Accounts payable & Other current liabilities | 18834 | 17397 |
|  |  |  | Current liabilities related to business combinations and to non-controlling interests | 105 | 137 |
| Inventories, accounts receivable and other current assets | 20916 | 19854 | Current income tax liabilities | 574 | 309 |
| Current income tax assets | 374 | 612 | Current lease liabilities | 277 | 269 |
| Cash and cash equivalents | 12736 | 10098 | Short-term debt and current portion of long-term debt | 4174 | 3183 |
| **Current assets** | **34026** | **30564** | **Current liabilities** | **23964** | **21295** |
| Assets held for sale or exchange | 85 | 89 | Liabilities related to assets held for sale or exchange | 10 | 0 |
| **Total assets** | &nbsp;&nbsp;&nbsp;&nbsp;**124585** | &nbsp;&nbsp;&nbsp;&nbsp;**120242** | **Total equity and liabilities** | &nbsp;&nbsp;&nbsp;&nbsp;**124585** | &nbsp;&nbsp;&nbsp;&nbsp;**120242** |

---

------

*Appendix 7: Other current operating income net of expenses – Regeneron Alliances*

---

| | | |
|:---|:---|:---|
| **€ million** | **2022** | **2021** |
| **Monoclonal Antibodies Alliance** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income & Expense related to profit/loss sharing | (2325) | (1253) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional share of profit paid by Regeneron related to development costs | 434 | &nbsp;&nbsp;&nbsp;&nbsp;127 |
| &nbsp;&nbsp;&nbsp;&nbsp;Regeneron commercial operating expenses reimbursement | (476) | &nbsp;&nbsp;&nbsp;&nbsp;(303) |
| &nbsp;&nbsp;&nbsp;**Total: Monoclonal Antibody Alliance** | **(2367)** | &nbsp;&nbsp;&nbsp;&nbsp;**(1429)** |
| **Immuno-Oncology Alliance** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Immuno-Oncology Alliance | **16** | **68** |
| **Other Regeneron** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total others related to Regeneron (mainly Libtayo<sup>®</sup> and Zaltrap<sup>®</sup>) <sup>(1)</sup> | **168** | **(12)** |
| **Total Regeneron Alliances** | **(2183)** | **(1373)** |

---

*(1) This line excludes an upfront payment of $900 million and a regulatory milestone payment of $100 million received by Sanofi from Regeneron in connection with the Amended IO Discovery Agreement signed in June 2022. These items are included in the Consolidated income statements line Other Operating Income.*

*Appendix 8: Currency sensitivity*

**2023 business EPS currency sensitivity**

---

| | | |
|:---|:---|:---|
| **Currency** | **Variation** | **Business EPS Sensitivity** |
| U.S. Dollar | +0.05 USD/EUR | -EUR 0.17 |
| Japanese Yen | +5 JPY/EUR | -EUR 0.02 |
| Chinese Yuan | +0.2 CNY/EUR | -EUR0.03 |
| Brazilian Real | +0.4 BRL/EUR | -EUR0.02 |
| Russian Ruble | +10 RUB/EUR | -EUR 0.02 |

---

**Currency exposure on Q4 2022 sales** 

---

| | |
|:---|:---|
| **Currency** | **Q4 2022** |
| US $ | 45.2% |
| Euro € | 21.1% |
| Chinese Yuan | 5.1% |
| Japanese Yen | 3.7% |
| Brazilian Real | 1.9% |
| Mexican pesos | 1.8% |
| Russian ruble | 1.5% |
| Canadian $ | 1.5% |
| Australian $ | 1.2% |
| British Pound | 1.2% |
| Others | 15.8% |

---

**Currency average rates** 

---

| | | | |
|:---|:---|:---|:---|
| | **Q4 2021** | **Q4 2022** | ***Change*** |
| €/$ | 1.144 | 1.021 | *-10.8 %* |
| €/Yen | 130.065 | 144.203 | *+10.9 %* |
| €/Yuan | 7.315 | 7.264 | *-0.7 %* |
| €/Real | 6.387 | 5.372 | *-15.9 %* |
| €/Ruble | 83.108 | 64.072 | *-22.9 %* |

---

------

*Appendix 9: Definitions of non-GAAP financial indicators*

**Company sales at constant exchange rates (CER)**

When we refer to changes in our net sales "at constant exchange rates" (CER), this means that we exclude the effect of changes in exchange rates.

We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.

**Reconciliation of net sales to Company sales at constant exchange rates for the fourth quarter and the full-year 2022**

---

| | | |
|:---|:---|:---|
| **€ million** | **Q4 2022** | **2022** |
| **Net sales** | **10,725** | **42,997** |
| Effect of exchange rates | 475 | 2,585 |
| **Company sales at constant exchange rates** | **10,250** | **40,412** |

---

**Business net income**

Sanofi publishes a key non-GAAP indicator. Business net income is defined as net income attributable to equity holders of Sanofi excluding:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• amortization of intangible assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impairment of intangible assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fair value remeasurement of contingent consideration related to business combinations or to disposals,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses arising from the impact of acquisitions on inventories

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restructuring costs and similar items<sup>(1)</sup>,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other gains and losses (including gains and losses on disposals of non-current assets<sup>(1)</sup>),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• costs or provisions associated with litigation<sup>(1)</sup>,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• tax effects related to the items listed above as well as effects of major tax disputes,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• net income attributable to non-controlling interests related to the items listed above.

*(1) Reported in the line items* ***Restructuring costs and similar items*** *and* ***Gains and losses on disposals, and litigation****, which are defined in Notes B.19. and B.20. to our consolidated financial statements.*

**Free cash flow** 

Free cash flow is a non-GAAP financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company's operations that is available for strategic investments<sup>1</sup> (net of divestments<sup>1</sup>), for debt repayment, and for capital return to shareholders. Free Cash Flow is determined from the Business Net Income adjusted for depreciation, amortization and impairment, share of profit/loss in associates and joint ventures net of dividends received, gains & losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions<sup>2</sup> net of disposal proceeds<sup>2</sup>, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities.

<sup>1</sup> *Amount of the transaction above a cap of €500 million per transaction (inclusive of all payments related to the transaction).*

<sup>2</sup> *Not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction).*

------

**Reconciliation from net cash provided by/(used in) operating activities to free cash flow**

---

| | | |
|:---|:---|:---|
| **€ million** | **2022** | **2021** |
| **Net cash provided by/(used in) operating activities in the Consolidated statements of cash flows**<sup>(1)</sup> | **10526** | **10522** |
| Acquisition of property, plant and equipment and software | (1656) | (1516) |
| Acquisitions of intangibles assets, investments and other long-term financial assets<sup>(2)</sup> | (824) | (1488) |
| Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes<sup>(2)</sup> | 1531 | 667 |
| Repayment of lease liabilities | (291) | (149) |
| Others<sup>(3)</sup> | (803) | 60 |
| **Free cash flow**<sup>(4)</sup> | **8483** | **8096** |

---

<sup>1</sup> *Most directly comparable IFRS measure to free cash flow.*

<sup>2</sup> *Transactions up to €500 million per transaction.*

<sup>3</sup> *In 2022, includes upfront payment of $900 million and regulatory milestone of $100 million received as part of Libtayo*<sup>®</sup> *license-out.*

<sup>4</sup> *Non IFRS indicator (see definition in Appendix 9).*

------

*Appendix 10: CSR dashboards*

---

| | | |
|:---|:---|:---|
| **Affordable access** | | |
| **Sanofi Global Health** | **Sanofi Global Health** | **Sanofi Global Health** |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| Malaria | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **9,276,504** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **23** countries | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **2,835,392** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **18** countries |
| Tuberculosis | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **146,356** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **28** countries | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **138,593** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **17** countries |
| NCD | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **40,439** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **16** countries | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **185,151** patients treated<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **28** countries |
| **Rare disease vials donation** | **Rare disease vials donation** | **Rare disease vials donation** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # Patients treated | **1083** | **1122** |
| #Vials donated | **109677** | **121025** |
| **Global access Plan** | **Global access Plan** | **Global access Plan** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # of access plan | Pilot phase in progress | Global access plan initiated for 2 assets |

---

---

| | | |
|:---|:---|:---|
| **R&D for unmet needs** | **R&D for unmet needs** | **R&D for unmet needs** |
| **Eradicate Polio** | **Eradicate Polio** | **Eradicate Polio** |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # Inactivated Polio Vaccine (IPV) doses supplied | **50.5 million** IPV doses supplied to UNICEF for GAVI countries | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**47 million** IPV doses supplied to UNICEF for GAVI countries |
| **Sleeping sickness elimination** | **Sleeping sickness elimination** | **Sleeping sickness elimination** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # Patients tested | **2** million | Data updated annually at Q2 23 |
| # Patients treated | **805** | Data updated annually at Q2 23 |
| **Pediatric cancer treatment development** | **Pediatric cancer treatment development** | **Pediatric cancer treatment development** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # of assets identified | 2 assets identified, preclinical studies started | •&nbsp;&nbsp;&nbsp;&nbsp;1 asset pre-clinical assessment complete<br>•&nbsp;&nbsp;&nbsp;&nbsp;1 asset in protocol preparation for clinical study<br>•&nbsp;&nbsp;&nbsp;&nbsp;1 additional asset identified for clinical development  |

---

------

---

| | | |
|:---|:---|:---|
| **Planet Care** | **Planet Care** | **Planet Care** |
| **Blister free vaccines** | **Blister free vaccines** | **Blister free vaccines** |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| % blister free syringe vaccines | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29%** of blister free syringe produced | **33%** of blister free syringe produced |
| **Eco design** | **Eco design** | **Eco design** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # of Life Cycle Analysis (LCA) | **4** LCAs completed | **7 LCAs completed & 1 in progress**<br>Eco-design digital solution launched |
| **Scope 1 & 2 emissions** | **Scope 1 & 2 emissions** | **Scope 1 & 2 emissions** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| GHG reduction vs 2019% | **-24.4%** | **-29.4%** |
| **Renewable electricity** | **Renewable electricity** | **Renewable electricity** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| % electricity consumption from renewable sources | **51.7%** | **62.0%** |
| **Eco car fleet** | **Eco car fleet** | **Eco car fleet** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| % eco car fleet on total car fleet | **26.2%** eco-fleet | **34.1%** eco-fleet |

---

---

| | | |
|:---|:---|:---|
| **In and beyond the workplace** | **In and beyond the workplace** | **In and beyond the workplace** |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| **Diverse Senior Leadership** | **Diverse Senior Leadership** | **Diverse Senior Leadership** |
| % of women | **34.2%** of our executives<br>**40.1%** of our senior leaders were women | **37.2%** of our executives<br>**41.7%** of our senior leaders were women |
| **Engagement with communities** | **Engagement with communities** | **Engagement with communities** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| # volunteers | **4,975** volunteers | **6,825** volunteers |
| # hours | **26,906** hours | **46,976** hours |
| **From Leaders to Citizens** | **From Leaders to Citizens** | **From Leaders to Citizens** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2021** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FY 2022** |
| KPI | Roll out planned in 2022 | More than half of the leaders have completed the initial eLearning phase |

---